Due to limited research support, the promise and potential of longevity medicine in existing interventions might not have been fully realized in most cases.
To address this, Ora Biomedical, Inc. developed the WormBot-AI, a robotics+AI platform that rapidly tested small molecules and other interventions for increased healthy lifespan in C. elegans. The webinar on 4 Apr 2024 discussed the transformation of longevity interventions at Ora Biomedical, Inc., a company focused on developing small molecule healthy aging therapeutics for humans, companion pets, and other organisms. Dr. Mitchell Lee, Chief Executive Officer, and Co-Founder of Ora Biomedical, Inc., shared the use of WormBot-AI for internal drug discovery research and the innovative “Million-Molecule Challenge” aimed at extending lifespan.